UPDATED Mar 22, 2024
Potentially undervalued companies with a strong past performance and robust balance sheet.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
BXPHARMA | ৳117.20 | -2.2% | -19.8% | ৳52.3b | ৳153.50 | PE10.6x | E15.0% | 3.0% | ||
SUPRIYA | ₹340.80 | 3.7% | 86.9% | ₹27.4b | ₹401.00 | PE22.8x | E21.6% | 0.2% | ||
RJF | €2.46 | -2.4% | -1.4% | €193.8m | €4.10 | PE20.6x | E46.1% | 1.6% | ||
1061 | HK$2.36 | 10.3% | -36.7% | HK$1.3b | HK$5.12 | PE4.9x | E28.7% | 3.8% | ||
PHO | kr57.50 | -3.8% | 2.7% | kr1.6b | kr86.00 | PE5837.4x | E88.3% | 0% | ||
4169 | NT$52.80 | -4.7% | 11.1% | NT$3.1b | NT$113.00 | PE232.3x | E59.5% | 0.06% | ||
PLX | US$1.27 | -4.5% | -36.2% | US$92.8m | US$13.00 | PE11.2x | E96.5% | n/a | ||
IBNSINA | ৳262.50 | 0.8% | -8.4% | ৳8.2b | ৳370.00 | PE12.6x | E14.5% | 2.3% | ||
7079 | JP¥4,680.00 | 2.2% | 0.8% | JP¥11.3b | JP¥9,000.00 | PE14.6x | E10.8% | n/a | ||
SHE | €3.80 | 1.1% | 3.3% | €43.2m | €8.08 | PE7.1x | E9.3% | 4.6% | ||
MAGLE | kr29.20 | 4.3% | 8.1% | kr315.4m | kr40.00 | PE25.9x | E41.2% | 1.2% |